No black box warning on record for Leqselvi

As of the latest FDA labeling reviewed, Leqselvi (DEURUXOLITINIB PHOSPHATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Leqselvi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Risk of LEQSELVI-Associated Serious Adverse Reactions in CYP2C9 Poor Metabolizers or with Concomitant Use of Moderate or Strong CYP2C9 Inhibitors : LEQSELVI is contraindicated in patients who are CYP2C9 poor metabolizers or patients taking a moderate or strong CYP2C9 inhibitor. ( 5.6 ) Gastrointestinal Perforations: Monitor patients who may be at increased risk

No black box warning on record for Leqselvi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Risk of LEQSELVI-Associated Serious Adverse Reactions in CYP2C9 Poor Metabolizers or with Concomitant Use of Moderate or Strong CYP2C9 Inhibitors : LEQSELVI is contraindicated in patients who are CYP2C9 poor metabolizers or patients taking a moderate or strong CYP2C9 inhibitor. ( 5.6 ) Gastrointestinal Perforations: Monitor patients who may be at increased risk

Leqselvi Black Box Warning

No black box warning on record for Leqselvi

Other warnings & precautions

Leqselvi Black Box Warning

No black box warning on record for Leqselvi

Other warnings & precautions